{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:28:36Z","timestamp":1790688516268,"version":"4.1.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Enfortumab vedotin is an antibody\u2013drug conjugate used for treatment of urothelial cancer. It has recently been associated with several reports of Stevens Johnson syndrome\/toxic epidermal necrolysis (TEN). In this report, we describe the case of a 63-year-old man who developed widespread, near full\u2013thickness desquamation, clinically mimicking TEN but with histologic features of toxic erythema of chemotherapy. This distinction is significant because it may have implications for prognosis and treatment. Further investigation is needed to ascertain the incidence of true TEN versus clinical imitators in patients with enfortumab vedotin\u2013related cutaneous toxicity.<\/jats:p>","DOI":"10.1097\/dad.0000000000002255","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T15:38:38Z","timestamp":1659713918000},"page":"933-935","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Enfortumab Vedotin\u2013Associated Toxic Epidermal Necrolysis-like Toxic Erythema of Chemotherapy"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0169-9813","authenticated-orcid":false,"given":"Suzanne W.","family":"Birmingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina N.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin-associated skin reactions reported as Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol."},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"621591","DOI":"10.3389\/fonc.2021.621591","article-title":"Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal stevens-johnson syndrome\/toxic epidermal necrolysis to dermal hypersensitivity reaction","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol."},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2020.10.020","article-title":"A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis","volume":"7","author":"Francis","year":"2021","journal-title":"JAAD Case Rep."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1038\/oncsis.2014.32","article-title":"Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer","volume":"3","author":"Lattanzio","year":"2014","journal-title":"Oncogenesis."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jdcr.2021.07.010","article-title":"Toxic epidermal necrolysis-like toxic erythema of chemotherapy: 2 illustrative cases","volume":"15","author":"Lu","year":"2021","journal-title":"JAAD Case Rep."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jdcr.2016.08.016","article-title":"Malignant intertrigo: a subset of toxic erythe ma of chemotherapy requiring recognition","volume":"2","author":"Smith","year":"2016","journal-title":"JAAD Case Rep."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1073\/pnas.1717705115","article-title":"Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer","volume":"115","author":"Powell Gray","year":"2018","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:06:06Z","timestamp":1750097166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002255","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,19]]}}}